Analysis of overall survival predictors. Cox proportional hazard model with shared frailty. (n = 2030)
| . | Univariable analysis . | Multivariable analysisa . | ||
|---|---|---|---|---|
| HR (95% CI) . | P . | HR (95% CI) . | P . | |
| Age (continuous, per 5 years increase) | 1.16 (1.11–1.21) | <0.001 | 1.19 (1.14–1.24) | <0.001 |
| Male | 1.29 (1.03–1.62) | 0.025 | 1.25 (0.99–1.58) | 0.060 |
| Myasthenia gravis | 0.68 (0.51–0.89) | 0.005 | 1.11 (0.84–1.48) | 0.451 |
| T size (continuous, per 1 cm increase) | 1.07 (1.03–1.11) | 0.001 | 1.04 (1–1.09) | 0.073 |
| Masaoka stage | ||||
| 1 (Ref) | 1 | – | 1 | – |
| 2 | 1.38 (0.96–2.00) | 0.084 | 1.09 (0.75–1.60) | 0.655 |
| 3 | 3.58 (2.51–5.13) | <0.001 | 2.66 (1.80–3.92) | <0.001 |
| 4 | 7.43 (5.16–10.70) | <0.001 | 4.41 (2.67–7.26) | <0.001 |
| Diagnosis | ||||
| Thymoma WHO A-AB-B1 (Ref) | 1 | – | 1 | – |
| Thymoma WHO B2-B3 | 1.40 (1.07–1.82) | 0.013 | 1.09 (0.82–1.46) | 0.553 |
| NETT | 4.76 (2.55–8.87) | <0.001 | 2.59 (1.35–4.99) | 0.004 |
| Thymic carcinoma | 4.49 (3.27–6.15) | <0.001 | 2.9 (1.68–3.40) | <0.001 |
| R status (R+ vs R0) | 3.87 (2.82–5.30) | <0.001 | 1.74 (1.18–2.57) | 0.007 |
| Year of intervention | ||||
| 1990–1995 (Ref) | 1 | – | 1 | – |
| 1996–2001 | 1.25 (0.83–1.86) | 0.282 | 1.09 (0.73–1.62) | 0.690 |
| 2002–2007 | 1.44 (0.93–2.23) | 0.099 | 1.05 (0.68–1.64) | 0.816 |
| 2008–2011 | 1.27 (0.71–2.27) | 0.427 | 1.07 (0.60–1.94) | 0.812 |
| Mean number patients (yearly) | ||||
| ≤4 (Ref) | 1 | – | 1 | – |
| 5–9 | 1.09 (0.55–2.17) | 0.797 | 1.75 (0.89–3.44) | 0.102 |
| ≥10 | 0.64 (0.28–1.50) | 0.309 | 0.92 (0.41–2.06) | 0.838 |
| . | Univariable analysis . | Multivariable analysisa . | ||
|---|---|---|---|---|
| HR (95% CI) . | P . | HR (95% CI) . | P . | |
| Age (continuous, per 5 years increase) | 1.16 (1.11–1.21) | <0.001 | 1.19 (1.14–1.24) | <0.001 |
| Male | 1.29 (1.03–1.62) | 0.025 | 1.25 (0.99–1.58) | 0.060 |
| Myasthenia gravis | 0.68 (0.51–0.89) | 0.005 | 1.11 (0.84–1.48) | 0.451 |
| T size (continuous, per 1 cm increase) | 1.07 (1.03–1.11) | 0.001 | 1.04 (1–1.09) | 0.073 |
| Masaoka stage | ||||
| 1 (Ref) | 1 | – | 1 | – |
| 2 | 1.38 (0.96–2.00) | 0.084 | 1.09 (0.75–1.60) | 0.655 |
| 3 | 3.58 (2.51–5.13) | <0.001 | 2.66 (1.80–3.92) | <0.001 |
| 4 | 7.43 (5.16–10.70) | <0.001 | 4.41 (2.67–7.26) | <0.001 |
| Diagnosis | ||||
| Thymoma WHO A-AB-B1 (Ref) | 1 | – | 1 | – |
| Thymoma WHO B2-B3 | 1.40 (1.07–1.82) | 0.013 | 1.09 (0.82–1.46) | 0.553 |
| NETT | 4.76 (2.55–8.87) | <0.001 | 2.59 (1.35–4.99) | 0.004 |
| Thymic carcinoma | 4.49 (3.27–6.15) | <0.001 | 2.9 (1.68–3.40) | <0.001 |
| R status (R+ vs R0) | 3.87 (2.82–5.30) | <0.001 | 1.74 (1.18–2.57) | 0.007 |
| Year of intervention | ||||
| 1990–1995 (Ref) | 1 | – | 1 | – |
| 1996–2001 | 1.25 (0.83–1.86) | 0.282 | 1.09 (0.73–1.62) | 0.690 |
| 2002–2007 | 1.44 (0.93–2.23) | 0.099 | 1.05 (0.68–1.64) | 0.816 |
| 2008–2011 | 1.27 (0.71–2.27) | 0.427 | 1.07 (0.60–1.94) | 0.812 |
| Mean number patients (yearly) | ||||
| ≤4 (Ref) | 1 | – | 1 | – |
| 5–9 | 1.09 (0.55–2.17) | 0.797 | 1.75 (0.89–3.44) | 0.102 |
| ≥10 | 0.64 (0.28–1.50) | 0.309 | 0.92 (0.41–2.06) | 0.838 |
NETT: neuroendocrine thymic tumour.
aAll effects were unadjusted for T size, whereas T size effect was unadjusted for Masaoka stage.
Analysis of overall survival predictors. Cox proportional hazard model with shared frailty. (n = 2030)
| . | Univariable analysis . | Multivariable analysisa . | ||
|---|---|---|---|---|
| HR (95% CI) . | P . | HR (95% CI) . | P . | |
| Age (continuous, per 5 years increase) | 1.16 (1.11–1.21) | <0.001 | 1.19 (1.14–1.24) | <0.001 |
| Male | 1.29 (1.03–1.62) | 0.025 | 1.25 (0.99–1.58) | 0.060 |
| Myasthenia gravis | 0.68 (0.51–0.89) | 0.005 | 1.11 (0.84–1.48) | 0.451 |
| T size (continuous, per 1 cm increase) | 1.07 (1.03–1.11) | 0.001 | 1.04 (1–1.09) | 0.073 |
| Masaoka stage | ||||
| 1 (Ref) | 1 | – | 1 | – |
| 2 | 1.38 (0.96–2.00) | 0.084 | 1.09 (0.75–1.60) | 0.655 |
| 3 | 3.58 (2.51–5.13) | <0.001 | 2.66 (1.80–3.92) | <0.001 |
| 4 | 7.43 (5.16–10.70) | <0.001 | 4.41 (2.67–7.26) | <0.001 |
| Diagnosis | ||||
| Thymoma WHO A-AB-B1 (Ref) | 1 | – | 1 | – |
| Thymoma WHO B2-B3 | 1.40 (1.07–1.82) | 0.013 | 1.09 (0.82–1.46) | 0.553 |
| NETT | 4.76 (2.55–8.87) | <0.001 | 2.59 (1.35–4.99) | 0.004 |
| Thymic carcinoma | 4.49 (3.27–6.15) | <0.001 | 2.9 (1.68–3.40) | <0.001 |
| R status (R+ vs R0) | 3.87 (2.82–5.30) | <0.001 | 1.74 (1.18–2.57) | 0.007 |
| Year of intervention | ||||
| 1990–1995 (Ref) | 1 | – | 1 | – |
| 1996–2001 | 1.25 (0.83–1.86) | 0.282 | 1.09 (0.73–1.62) | 0.690 |
| 2002–2007 | 1.44 (0.93–2.23) | 0.099 | 1.05 (0.68–1.64) | 0.816 |
| 2008–2011 | 1.27 (0.71–2.27) | 0.427 | 1.07 (0.60–1.94) | 0.812 |
| Mean number patients (yearly) | ||||
| ≤4 (Ref) | 1 | – | 1 | – |
| 5–9 | 1.09 (0.55–2.17) | 0.797 | 1.75 (0.89–3.44) | 0.102 |
| ≥10 | 0.64 (0.28–1.50) | 0.309 | 0.92 (0.41–2.06) | 0.838 |
| . | Univariable analysis . | Multivariable analysisa . | ||
|---|---|---|---|---|
| HR (95% CI) . | P . | HR (95% CI) . | P . | |
| Age (continuous, per 5 years increase) | 1.16 (1.11–1.21) | <0.001 | 1.19 (1.14–1.24) | <0.001 |
| Male | 1.29 (1.03–1.62) | 0.025 | 1.25 (0.99–1.58) | 0.060 |
| Myasthenia gravis | 0.68 (0.51–0.89) | 0.005 | 1.11 (0.84–1.48) | 0.451 |
| T size (continuous, per 1 cm increase) | 1.07 (1.03–1.11) | 0.001 | 1.04 (1–1.09) | 0.073 |
| Masaoka stage | ||||
| 1 (Ref) | 1 | – | 1 | – |
| 2 | 1.38 (0.96–2.00) | 0.084 | 1.09 (0.75–1.60) | 0.655 |
| 3 | 3.58 (2.51–5.13) | <0.001 | 2.66 (1.80–3.92) | <0.001 |
| 4 | 7.43 (5.16–10.70) | <0.001 | 4.41 (2.67–7.26) | <0.001 |
| Diagnosis | ||||
| Thymoma WHO A-AB-B1 (Ref) | 1 | – | 1 | – |
| Thymoma WHO B2-B3 | 1.40 (1.07–1.82) | 0.013 | 1.09 (0.82–1.46) | 0.553 |
| NETT | 4.76 (2.55–8.87) | <0.001 | 2.59 (1.35–4.99) | 0.004 |
| Thymic carcinoma | 4.49 (3.27–6.15) | <0.001 | 2.9 (1.68–3.40) | <0.001 |
| R status (R+ vs R0) | 3.87 (2.82–5.30) | <0.001 | 1.74 (1.18–2.57) | 0.007 |
| Year of intervention | ||||
| 1990–1995 (Ref) | 1 | – | 1 | – |
| 1996–2001 | 1.25 (0.83–1.86) | 0.282 | 1.09 (0.73–1.62) | 0.690 |
| 2002–2007 | 1.44 (0.93–2.23) | 0.099 | 1.05 (0.68–1.64) | 0.816 |
| 2008–2011 | 1.27 (0.71–2.27) | 0.427 | 1.07 (0.60–1.94) | 0.812 |
| Mean number patients (yearly) | ||||
| ≤4 (Ref) | 1 | – | 1 | – |
| 5–9 | 1.09 (0.55–2.17) | 0.797 | 1.75 (0.89–3.44) | 0.102 |
| ≥10 | 0.64 (0.28–1.50) | 0.309 | 0.92 (0.41–2.06) | 0.838 |
NETT: neuroendocrine thymic tumour.
aAll effects were unadjusted for T size, whereas T size effect was unadjusted for Masaoka stage.
This PDF is available to Subscribers Only
View Article Abstract & Purchase OptionsFor full access to this pdf, sign in to an existing account, or purchase an annual subscription.
